-
1
-
-
22044440986
-
-
A. Green, K.A. Ellis, J. Ellis, C.F. Bartholomeusz, S. Ilic, R.J. Croft, K.L. Phan, and P.J. Nathan Pharmacol. Biochem. Behav. 81 2005 575
-
(2005)
Pharmacol. Biochem. Behav.
, vol.81
, pp. 575
-
-
Green, A.1
Ellis, K.A.2
Ellis, J.3
Bartholomeusz, C.F.4
Ilic, S.5
Croft, R.J.6
Phan, K.L.7
Nathan, P.J.8
-
3
-
-
68349130498
-
-
C. Gotti, F. Clementi, A. Fornari, A. Gaimarri, S. Guiducci, I. Manfredi, M. Moretti, P. Pedrazzi, L. Pucci, and M. Zoli Biochem. Pharmacol. 78 2009 703
-
(2009)
Biochem. Pharmacol.
, vol.78
, pp. 703
-
-
Gotti, C.1
Clementi, F.2
Fornari, A.3
Gaimarri, A.4
Guiducci, S.5
Manfredi, I.6
Moretti, M.7
Pedrazzi, P.8
Pucci, L.9
Zoli, M.10
-
4
-
-
34247486496
-
-
L.M. Broad, E. Sher, P.C. Astles, R. Zwart, and M.J. O'Neill Drugs Future 32 2007 161
-
(2007)
Drugs Future
, vol.32
, pp. 161
-
-
Broad, L.M.1
Sher, E.2
Astles, P.C.3
Zwart, R.4
O'Neill, M.J.5
-
5
-
-
0034732116
-
-
S. Leonard, C. Breese, C. Adams, K. Benhammou, J. Gault, K. Stevens, M. Lee, L. Adler, A. Olincy, S.R. Ros, and R. Freedman Eur. J. Pharmacol. 393 2000 237
-
(2000)
Eur. J. Pharmacol.
, vol.393
, pp. 237
-
-
Leonard, S.1
Breese, C.2
Adams, C.3
Benhammou, K.4
Gault, J.5
Stevens, K.6
Lee, M.7
Adler, L.8
Olincy, A.9
Ros, S.R.10
Freedman, R.11
-
6
-
-
19244378105
-
-
E. Perry, C. Martin-Ruiz, M. Lee, M. Griffiths, M. Johnson, M. Piggott, V. Haroutunian, J.D. Buxbaum, J. Nãsland, K. Davis, C. Gotti, F. Clementi, S. Tzartos, O. Cohen, H. Soreq, E. Jaros, R. Perry, C. Ballard, I. McKeith, and J. Court Eur. J. Pharmacol. 393 2000 215
-
(2000)
Eur. J. Pharmacol.
, vol.393
, pp. 215
-
-
Perry, E.1
Martin-Ruiz, C.2
Lee, M.3
Griffiths, M.4
Johnson, M.5
Piggott, M.6
Haroutunian, V.7
Buxbaum, J.D.8
Nãsland, J.9
Davis, K.10
Gotti, C.11
Clementi, F.12
Tzartos, S.13
Cohen, O.14
Soreq, H.15
Jaros, E.16
Perry, R.17
Ballard, C.18
McKeith, I.19
Court, J.20
more..
-
7
-
-
84891495896
-
-
WO2012099836 A1 (PCT)
-
Bencherif, M.; Dunbar, G. C.; Hosford, D. A.; Gatto, G. J.; Hauser, T.; Jordan, K. G.; Segreti, A.C. Treatment of Cognitive Dysfunction in Schizophrenia, WO2012099836 A1 (PCT), 2012.
-
(2012)
Treatment of Cognitive Dysfunction in Schizophrenia
-
-
Bencherif, M.1
Dunbar, G.C.2
Hosford, D.A.3
Gatto, G.J.4
Hauser, T.5
Jordan, K.G.6
Segreti, A.C.7
-
10
-
-
20944441082
-
-
R.S. Hurst, M. Hajós, M. Raggenbass, T.M. Wall, N.R. Higdon, J.A. Lawson, K.L. Rutherford-Root, M.B. Berkenpas, W.E. Hoffmann, D.W. Piotrowski, V.E. Groppi, G. Allaman, R. Ogier, S. Bertrand, D. Bertrand, and S.P. Arneric J. Neurosci. 25 2005 4396
-
(2005)
J. Neurosci.
, vol.25
, pp. 4396
-
-
Hurst, R.S.1
Hajós, M.2
Raggenbass, M.3
Wall, T.M.4
Higdon, N.R.5
Lawson, J.A.6
Rutherford-Root, K.L.7
Berkenpas, M.B.8
Hoffmann, W.E.9
Piotrowski, D.W.10
Groppi, V.E.11
Allaman, G.12
Ogier, R.13
Bertrand, S.14
Bertrand, D.15
Arneric, S.P.16
-
12
-
-
84891488750
-
-
As the nAChα7 receptor is a calcium permeable ion channel, the activity of this receptor can be measured in cell lines expressing the target using calcium sensitive dyes. In this paper, we used a rat GH4C1 cell line with stable expression of nAChα7 receptors. The cells were seeded in 384-well plates and loaded with a calcium sensitive dye (calcium-4). The α7 receptor was activated with 20 μM ACh and the activity of new compounds was measured as a change in fluorescence between control ± compounds, measured on a FDSS 700 reader. PNU-120596 was used as positive control and the max stimulation of new compounds was calculated relative to PNU-120596 defined as 100%.
-
As the nAChα7 receptor is a calcium permeable ion channel, the activity of this receptor can be measured in cell lines expressing the target using calcium sensitive dyes. In this paper, we used a rat GH4C1 cell line with stable expression of nAChα7 receptors. The cells were seeded in 384-well plates and loaded with a calcium sensitive dye (calcium-4). The α7 receptor was activated with 20 μM ACh and the activity of new compounds was measured as a change in fluorescence between control ± compounds, measured on a FDSS 700 reader. PNU-120596 was used as positive control and the max stimulation of new compounds was calculated relative to PNU-120596 defined as 100%.
-
-
-
-
13
-
-
84891488611
-
-
All aqueous solubilities were determined in phosphate buffer pH 7.4 based on crystalline material. For 2 the aqueous solubility measurement was based on crystalline or partly crystalline material.
-
All aqueous solubilities were determined in phosphate buffer pH 7.4 based on crystalline material. For 2 the aqueous solubility measurement was based on crystalline or partly crystalline material.
-
-
-
-
14
-
-
84891493313
-
-
c log P was calculated using Daylight Version 4.9 from Daylight Chemical Information Systems, Inc.
-
c log P was calculated using Daylight Version 4.9 from Daylight Chemical Information Systems, Inc.
-
-
-
-
15
-
-
84891485465
-
-
The absolute configuration was performed by comparing optical rotary power with literature values.
-
The absolute configuration was performed by comparing optical rotary power with literature values.
-
-
-
-
16
-
-
84891484824
-
-
50 values and maximum stimulation was calculated for the new compounds. Retigabine was used as standard positive control.
-
50 values and maximum stimulation was calculated for the new compounds. Retigabine was used as standard positive control.
-
-
-
-
17
-
-
84891489610
-
-
3) Kozikowski et al., J. Med. Chem. 2009, 52, 1885; Lit: [α] D 20 = + 311.7 (c 1.776, EtOH) Walborsky et al., Tetrahedron 1964, 20, 1695).
-
3) Kozikowski et al., J. Med. Chem. 2009, 52, 1885; Lit: [α] D 20 = + 311.7 (c 1.776, EtOH) Walborsky et al., Tetrahedron 1964, 20, 1695).
-
-
-
-
19
-
-
84891487389
-
-
In all cases, the dextrorotary trans 2-phenyl-cyclopropanecarboxylic acids were used for further synthesis.
-
In all cases, the dextrorotary trans 2-phenyl-cyclopropanecarboxylic acids were used for further synthesis.
-
-
-
-
25
-
-
64249168387
-
-
J.W. Young, S.B. Powell, V. Risbrough, H.M. Marston, and M.A. Geyer Pharmacol. Ther. 122 2009 150
-
(2009)
Pharmacol. Ther.
, vol.122
, pp. 150
-
-
Young, J.W.1
Powell, S.B.2
Risbrough, V.3
Marston, H.M.4
Geyer, M.A.5
-
28
-
-
84862659903
-
-
J.P. Redrobe, L. Elster, K. Frederiksen, C. Bundgaard, I.E. de Jong, G.P. Smith, A.T. Bruun, P.H. Larsen, and M. Didriksen Psychopharmacology 221 2012 451
-
(2012)
Psychopharmacology
, vol.221
, pp. 451
-
-
Redrobe, J.P.1
Elster, L.2
Frederiksen, K.3
Bundgaard, C.4
De Jong, I.E.5
Smith, G.P.6
Bruun, A.T.7
Larsen, P.H.8
Didriksen, M.9
-
29
-
-
84891483078
-
-
Male Lister Hooded rats (Charles River, Crl:LH, Germany; 220-240 g) were administered subPCP (synthesized at H. Lundbeck A/S, dissolved in 0.9% saline; 5 mg/kg, 1 ml/kg, ip bid for 7 days) or saline (1 ml/kg ip bid for 7 days) at 7 am and 7 pm, followed by a 7-day washout period prior to behavioural testing. Lu AF58801 (dissolved in 100% PEG400) was administered 30 min prior to the acquisition trial of the NOR procedure via the po route. Data is presented as the discrimination index, calculated as the novel object exploration time (Tn) minus the familiar object exploration time (Tf) divided by the total exploration time (Tn + Tf). One-way ANOVA, followed by appropriate All-Pairwise Multiple Comparison post-hoc analysis (Bonferroni's t-test) was used to investigate statistical differences between test groups (P < 0.05).
-
Male Lister Hooded rats (Charles River, Crl:LH, Germany; 220-240 g) were administered subPCP (synthesized at H. Lundbeck A/S, dissolved in 0.9% saline; 5 mg/kg, 1 ml/kg, ip bid for 7 days) or saline (1 ml/kg ip bid for 7 days) at 7 am and 7 pm, followed by a 7-day washout period prior to behavioural testing. Lu AF58801 (dissolved in 100% PEG400) was administered 30 min prior to the acquisition trial of the NOR procedure via the po route. Data is presented as the discrimination index, calculated as the novel object exploration time (Tn) minus the familiar object exploration time (Tf) divided by the total exploration time (Tn + Tf). One-way ANOVA, followed by appropriate All-Pairwise Multiple Comparison post-hoc analysis (Bonferroni's t-test) was used to investigate statistical differences between test groups (P < 0.05).
-
-
-
|